Sanofi

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:39:00 2024-07-10 am EDT			After market 03:59:59 pm
93.55 ^EUR	+1.65%		94.1	+0.59%

11:13pm	US Senator Sanders optimistic Novo Nordisk can be pressured to cut Wegovy, Ozempic prices	RE
12:48pm	SANOFI : Receives a Sell rating from Deutsche Bank	ZD

Sanofi Begins Sales of Soliqua Injection for Type 2 Diabetes Through US Pharmacies

January 04, 2017 at 10:51 am EST

Sanofi announced that Soliqua 100/33 injection is now available by prescription in US pharmacies for type 2 diabetes after getting approval from the US Food and Drug Administration in November. The medicine is indicated for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin less than 60 Units daily or lixisenatide.

Latest news about Sanofi

US Senator Sanders optimistic Novo Nordisk can be pressured to cut Wegovy, Ozempic prices	05:13pm	RE
SANOFI : Receives a Sell rating from Deutsche Bank	06:48am	ZD
SANOFI : UBS reiterates its buy recommendation	Jul. 09	CF
Sector Update: Health Care Stocks Flat to Higher Premarket Tuesday	Jul. 09	MT
SANOFI : UBS maintains a Buy rating	Jul. 09	ZD
Kymera Reports Expansion of KT-474 Trials; Shares Rise After-Hours	Jul. 08	MT
Kymera Therapeutics, Inc. Announces Expansion of KT-474 HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy	Jul. 08	CI
SANOFI : Jefferies maintains a Buy rating	Jul. 08	ZD
SANOFI : Stifel slightly raises its target on the stock	Jul. 08	CF
That's not so bad, is it?	Jul. 08
Sector Update: Health Care Stocks Steady Premarket Friday	Jul. 05	MT
Sector Update: Health Care	Jul. 05	MT
GlaxoSmithkline Pharmaceuticals Limited Announces Change in Management	Jul. 05	CI
Sanofi's Consumer Health Unit Receives Interest from French State	Jul. 04	MT
Bpifrance eyes investment in Sanofi's consumer health business	Jul. 04	RE
Bain Capital, Cinven, Others Said Mulling Bids for Sanofi's Consumer Health Unit	Jul. 04	MT
Bain, Cinven Explore Joint Bid for Sanofi's Consumer Unit, Bloomberg Reports	Jul. 04	DJ
Paul Hudson, CEO of Sanofi: AI to improve organisational efficiency	Jul. 03	MT
Bain, Cinven Said to Weigh Joint Bid for Sanofi's Consumer Health Division	Jul. 03	MT
Bain, Cinven Said to Weigh Joint Bid for Sanofi's Consumer Health Division	Jul. 03	MT
Bain, Cinven Said to Weigh Joint Bid for Sanofi's Consumer Health Division, Bloomberg Reports	Jul. 03	MT
SANOFI : Berenberg reiterates its Buy rating	Jul. 03	ZD
SANOFI : JP Morgan remains Neutral	Jul. 03	ZD
Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits	Jul. 03	MT
Sanofi Blockbuster Drug Dupixent Gets First-in-World Approval in Europe for COPD	Jul. 03	MT

Chart Sanofi

Duration

Period

More charts

Company Profile

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).

Sector

Pharmaceuticals

Calendar

2024-07-25 - Q2 2024 Earnings Release

Related indices

CAC 40 , Euro STOXX 50 Index , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Paul Hudson, CEO of Sanofi: AI to improve organisational efficiency

July 03, 2024 at 04:01 pm EDT

SANOFI : Sanofi’s healthy Q1 performance hailed by markets

April 25, 2024 at 07:58 am EDT

Sanofi : In the hot seat

October 30, 2023 at 06:52 am EDT

More Strategies

Ratings for Sanofi

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

92.03 EUR

Average target price

108.5 EUR

Spread / Average Target

+17.90%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SANOFI	+4.22%	124B
ELI LILLY AND COMPANY	+61.22%	840B
NOVO NORDISK A/S	+39.84%	621B
JOHNSON & JOHNSON	-4.66%	354B
MERCK & CO., INC.	+16.77%	319B
ABBVIE INC.	+8.50%	297B
ASTRAZENECA PLC	+13.94%	237B
NOVARTIS AG	+15.82%	221B
ROCHE HOLDING AG	+1.84%	220B
AMGEN INC.	+11.68%	169B

Other Pharmaceuticals

Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Sanofi Begins Sales of Soliqua Injection for Type 2 Diabetes Through US Pharmacies

EPS Revisions